Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Anytime I have a question it is answered quickly
Users who maintain adequate protein intake report significantly less hair thinning and better skin elasticity during weight loss
Retatrutide Sexual Function Impact: What the Phase 2 Data Actually Show At a glance Drug / retatrutide (LY3437943), investigational triple GIP/GLP-1/glucagon receptor agonist Phase 2 trial / Jastreboff et al., NEJM 2023, N=338 adults with obesity Peak weight loss / 24.2% mean body-weight reduction at 48 weeks (12 mg dose) Sexual-function endpoints / not prespecified in Phase 2
Acknowledgments We thank the laboratory staff for technical assistance and the accounting and human resources departments for administrative support, and the Research Council of Lithuania for financial support
[Updated 2024 Oct 6]
US$ 24.72
US$ 25.35
US$ 25.07
US$ 23.45
US$ 27.54
US$ 23.45
US$ 21.88
US$ 27.45
US$ 28.42
US$ 27.76
US$ 25.60
